The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
AffiDX was 100% sensitive for the delta variant up to ct29. Furtermore the tests they benchmarked against were 50% and 0% sensitive. I think that piece of news was overlooked by many but not by potential large scale customers.
AffiDX is needed more than ever, just looked at what has happened in Scotland following the schools reopening. We will certainly see the same happening in England and winter is around the corner, the delta variant has changed everything.
I know it’s not a popular belief amongst most shareholders these days, but I still firmly believe that Avacta’s almost weird silence about AffiDX reeks of Government involvement. Why wouldn’t Avacta be shouting about AffiDX from the rooftops and it’s performance against Delta. Added with the recent procurement pathway changes, everything is well and truly in play with with a Government contract. Not that it matters as Avacta will sell everything it makes, but it obviously helps with securing manufacturing capacity and the obvious P.R. that a goverment contract would bring.
Big few weeks coming up for Avacta. Outside of AffiDX I think we must be close now to news out of AffyXell and 1st in vivo data, LG chem update and possible IND for PD-L1/XT Affimer and full in vivo data set for the TMAC - the Jewell in the crown imo. Of course AVA6000 is chugging away nicely in the background and I imagine it’s going to be very hard to hide any excitement about early data during the business update, after all it will have passed previous maximum tolerated dose by that point.
Nobody can deny the past 2 months have been hugely frustrating in terms of the share price, but the delays are just that just delays. Avacta have the best rapid test in the world imo and will sell everything they make, regardless of capacity. The therapeutics will come under much more focus now with AVA6000 on the clinic and the partnered programmes maturing fast.
I’ve never been more confident in Avacta’s potential and as I’m not a trader the recent weakness in share price hasn’t bothered me in the slightest. In fact I took the opportunity to top up significantly and have now reached my target holding far sooner then I thought I would. I firmly believe we will see a big rebate this month and in Al’s word…..”I’m really looking forward it it”
GLA as always.
"We are very excited to announce that we have been selected by Avacta Life Sciences to enter a strategic relationship for the provision of global sample management services to support Avacta’s clinical development portfolio.
We are delighted to be working with Avacta Life Sciences, Therapeutics Division and are very much looking forward to a successful partnership"
#clinicaltrials #clinicaloperations #samplemanagement
#biotechnology #samplepreparation #sampleprocessing
https://www.linkedin.com/posts/colibriscientific_avacta-life-sciences-and-colibri-scientific-activity-6835518297631457280-or2r/
Avacta been tagged in the following post
https://www.linkedin.com/posts/national-horizons-centre_viralvectors-activity-6834101720759447553-lpMS/
REGISTER NOW for our #viralvectors manufacturing training course - September 6th to 10th 2021.
Delivered in partnership with CPI our Viral Vectors Manufacturing training course covers the production of viral vectors, their optimisation and scale-up.
Cobra Biologics, A Charles River Company eXmoor Pharma Concepts Ltd Autolus Ltd. FreelineTony Hitch**** Corrine Ward FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy Catapult GSK AstraZeneca Novartis Orchard Therapeutics Oxford Biomedica Adaptimmune Amgen bluebird bio Ori Biotech Sarah Gilbert Vaccitech The Vaccines Manufacturing and Innovation Centre (VMIC UK) Prokarium Avacta
.At first i was puzzled as to why Avacta was being mentioned, but then I recalled what Astrea's former sales director said about affimers.....
"In case you missed this exciting news...
Astrea can now offer both triazine and affimer based ligand technologies to support the development of custom affinity adsorbents.
This complementary technology greatly enhances our capabilities in ligand design and will benefit a wide range of applications including vaccine purification"
https://www.linkedin.com/posts/andydavies6_license-agreement-with-astrea-bioseparations-activity-6753264153676271616-XROD/
Just another billion dollar market that Affimers are involved in:)
I think it was @Soleboy that mentioned that more data on the TMAC’s was due to be realised next month. Avacta said in their February business update they would have the data before the end of the year.
It’s pretty reasonable to assume that Mr Goldberg is as close to that data as anyone. Just remember the 2nd TMAC put 60% of tumours in animal models into complete regression.
Successful AVA6000 data massively de-risks the TMAC concept as it proves they can release the toxin in the tumour micro environment, key to the TMAC.
Just remember Avacta and Tufts own the patent to this entire concept. Whether you want to create a Affimer, antibody, aptamer TMAC you have to licence through Avacta.
The market potential for Precision pro drugs and TMAC’s is absolutely astonishing IMO. Just how Avacta got escluvce rights to Tufts compound is beyond me, I think Al and Matt Vincent have to get alot of credit for that one.
Nice find gmcc.
I’m still a little perplexed as to why Avacta haven’t released more data around AVA3996 pro-velcade. Clearly they have data and it’s been shown to effective similar to AVA6000.
I’m still thinking Takeda will want to get there hands on AVA3996 especially with velcade coming off patent next year. Possibly they are already in discussion with Avacta/Tufts???
Great addition to the board and as for looking for signs…,,
A huge amount of the development works for the Precision and TMAC platforms is carried out by Tufts University in Boston. As one of the leading US medical schools I would imagine they have a very strong relationship with the US Cancer society, which Dr Goldberg is heavily involved in.
Also I’m fairly sure all of the animal work for AVA6000 and the 2 TMAC’s was carried out in conjunction with the US cancer society, but need to check that.
Anyway, clearly Avacta’s approach to treating cancer is getting a lot of attention stateside.
Couldn’t care less what the share price price does today.
My thoughts are with the patients and the hope that AVA6000 can play a big part in treating this horrible disease in a more effective and tolerable way.
Great news for patients and well done Avacta.
https://www.linkedin.com/posts/european-society-for-clinical-virology_escv2021-clinicalvirology-sarscov2-activity-6829335485261869057-waBs
Be sure to add Industry Symposium I sponsored by Avacta on September 15 (12:40 - 13:40 BST) to your agenda! Join Dr Alastair Smith, Professor Matthew Baylis, and Dr Matt Johnson for a focused discussion on the challenge of future pandemics.
Richard Hughes, Mahmud Kamani and associates own a significant chunk of LSAI and could look to reverse Medusa19 into LSAI by an RTO. This makes a lot of sense as I believe there are significant losses on the books at LSAI which can be offset against future profits coming out of Medusa19.
Nigel Burton who was appointed to LSAI's board recently also sits on Deepverge and Microsaic boards, both companies also working with Avacta.
https://www.locationsciencesgroup.ai/investor-relations/significant-shareholders/
https://news.sky.com/story/covid-19-delta-infections-produce-similar-levels-of-virus-regardless-of-vaccination-status-suggests-early-analysis-12374244
Didn't some wise Yorkshireman say testing would be at least 3 - 5 years and probably forever......
It certainly feels like tech transfer is now done with Abingdon Health, though you would think Avacta would announce this.
All the top brass at AH liked Avacta’s post on LinkedIn that delivery of AffiDX had commenced…..
Chris Hand - Chairman: Abingdon Health plc
Chris Yates - CEO of Abingdon Health Plc
Leigh Thomas - Senior VP, Director of Global Sales at Abingdon Health
Olly Gardner - Chief Operating Officer at Abingdon Health
Scott Page - Financial Director at Abingdon Health
Mark Jones - Technical Director at Abingdon Health
https://calibrescientific.com/en/products/ANACOV-BSV-COV-CA01#tabs-1
https://calibrescientific.com/en/products/ANACOV-BSV-COV-CA03
https://calibrescientific.com/en/products/ANACOV-BSV-COV-DET-05
LinkedIn likes of Avacta's update by Abingdon Health's top brass today....
Chris Hand - Chairman: Abingdon Health plc
Chris Yates - CEO of Abingdon Health Plc
Leigh Thomas - Senior VP, Director of Global Sales at Abingdon Health
Olly Gardner - Chief Operating Officer at Abingdon Health
In think tech transfer is done and their producing AffiDX now.
https://www.linkedin.com/posts/eliot-forster-5a6ba63_update-on-affidx-sars-cov-2-antigen-lateral-activity-6828575344241512448-QrUC/
"Delighted to see the progress of this U.K. lateral flow invention"
Well Chris Molloy is clearly happy about the progress of AffiDX.
Hi Jesk, Yes have total confidence in Avacta, its management and where the company is heading. I just don't see a better opportunity than Avacta right now. I was however fortunate to acquire the bulk of my shares below the current price and I fully appreciate that those that brought near the top are very frustrated right now.
The share price drop and investor frustration comes from imo what is perceived to be a disconnect between Alistair Smiths comments and what has been announced to date around AffiDX . I understand that, but Al has spoken about demand being there for at least 3-5 years, a view I certainly share. I believe Al's personal timelines are not in sync with what the market is deeming to be a short term opportunity, I absolutely am with Al on this one, testing will be around for years to come and Avacta and AffiDX are perfectly placed to benefit from that. Avacta are going to take their time and not be rushed, this about grabbing a lion share of the long term market and they cant afford to get it wrong and damage the brand or IP. AffiDX will sell in huge quantities moving forward, that I have no doubt in, bit the timelines may be a little longer getting there than some shareholders first thought.
Outside of AffiDX we have so many value inflection points coming up. In the next 6 months we should have a full in vivo data set for the 1st TMAC and 1st data coming from AffyXell and proof of concept. Obviously AVA6000 data which if successful will dramatically change the value of the company and most probably will attract massive offers for the group. We also probably have 1st data coming out of Point Biopharma, a deal I really like by the way in a very hot area of medicine right now. I could go on but you get the picture....
Avacta is one of the most diversified small biotech's around with so many shots on goal in the hottest areas of medicine. It is way ahead of the curve for such a young company in this space, both with the deals it has signed(all without human data by the way) and the speed in getting its 1st diagnostic product to market. It has a great axis leading the company in Alistair Smith, Neil Bell and Elliot Forster, who was recently voted one of the top 20 biotech leaders in the world. I also absolutely love its hybrid model of therapeutics and diagnostics divisions as it helps alleviate the dilution and funding issues all small biotech's face.
I'm no trader so I'm here for the long term and the current share price is a huge opportunity to be taken advantage of. My Avacta journey will probably end with the inevitable takeover, but at multiples far far in excess of todays price.
Hope that helps but as ever DYOR and look at the bigger picture.
GLA
Thanks Stodgy, but I certainly would never claim to the best poster here, we gave some brilliant posters with great knowledge and insights. Unfortunately we have either lost or have less input now from some of them now due to daily bile we get from the trolls.
I will continue to post as it all goes over the top of my head really and I still think there is a lot of value to be gained from contributing here.
https://bioservuk.com/wp-content/uploads/2021/06/BioServUK-–-AffiDX-Lateral-Flow-Test-–-Multilanguage-IFU-ENDEFRESIT-V1.2.pdf